Safety study pushes back phase 3 trial of Newron’s schizophrenia drug

Switzerland’s neurology specialist Newron must hold off starting a phase 3 study of its schizophrenia drug evenamide to complete a small study to show safety at a higher dose, causing a further delay to development.